2026 Biotimize. All rights reserved.

Biotimize

Biotimize is a specialized CDMO bridging the gap between benchtop Drug Discovery/ PoC and GMP compliance for global biotechs and pharma.

Accelerating Biomanufacturing from DNA to Clinical Readiness

Scroll Down for more

Biotimize is Brazil's premier CDMO specializing in bioprocess development, cell line engineering, and non-clinical readiness for complex biopharmaceuticals.

We bridge the critical gap between early-stage discovery and scalable, GMP-compliant industrial production (TRL 6). By combining proprietary cell platforms (mammalian & microbial), structured Quality Assurance, and deep regulatory expertise, we empower biotechs, pharma leaders, and public institutions to de-risk pipeline expansion and fast-track market access.

Bioproduct Development

Strategic Expansion

Coming soon
Future-Proofing Infrastructure: As part of our long-term growth masterplan, Biotimize is advancing the development of a 20,000+ m² GMP production site designed to scale R&D and commercial biomanufacturing capabilities, reinforcing our commitment to providing integrated end-to-end solutions for global partners.

Latest News

Bioprocess CDMO Institutional Partners Research
30, Jan 2026
A Nova Lei do CEIS (Lei nº 15.471/2026): PDP e PDIL

BR A Nova Lei do CEIS (Lei nº 15.471/2026): Como Preparar seu Pipeline de Biológicos para as Próximas Chamadas de PDP e PDIL A sanção da Lei nº 15.471/2026, que instituiu a Estratégia Nacional de Saúde do Complexo Econômico-Industrial da Saúde (Ensceis), marca uma mudança estrutural na soberania sanitária e na indústria farmacêutica brasileira. Instrumentos… Continue reading A Nova Lei do CEIS (Lei nº 15.471/2026): PDP e PDIL

Bioprocess CDMO Institutional Partners Research
08, Dec 2025
The FDA Has Changed Key Requirements for Biosimilars: What This Means — and Why Now Is the Right Time to Start Development

BR O FDA introduziu mudanças relevantes em suas orientações para biossimilares, reforçando a possibilidade de que, em muitos casos, estudos clínicos comparativos de eficácia podem não ser mais necessários, desde que haja um pacote robusto de evidências analíticas, de farmacocinética (PK) e imunogenicidade. Essa atualização representa um movimento global de simplificação regulatória e traz impactos… Continue reading The FDA Has Changed Key Requirements for Biosimilars: What This Means — and Why Now Is the Right Time to Start Development

Bioprocess CDMO Institutional Partners Research
28, Aug 2025
Biotimize: the bridge between translational science and biopharmaceutical self-sufficiency in Brazil

🇺🇸 In Brazil, the conversation about translational science has gained enormous relevance. The challenge of transforming scientific discoveries into therapies that truly reach patients requires more than research—it demands infrastructure, expertise, and the ability to scale innovation into real products. This is where Biotimize plays a unique and strategic role. As Brazil’s first Contract Development… Continue reading Biotimize: the bridge between translational science and biopharmaceutical self-sufficiency in Brazil

PHP Biotech
Cristalia
Crop Labs
Vyrobio
Bio Fiocruz
Eurofarma
UFRJ
FUNED
PHP Biotech
Cristalia
Crop Labs
Vyrobio
Bio Fiocruz
Eurofarma
UFRJ
FUNED

Get in touch with us

Biotimize is a specialized CDMO bridging the gap between benchtop PoC and GMP compliance. We deliver end-to-end cell line development, robust bioprocesses, and structured Quality Assurance for global biotechs and pharma.

LGPD

Rigorous company in relation to the general data protection law (LGPD)

Biotimize - Biotechnology as a Service is committed to complying with the laws that protect the privacy of the data of its employees, partners and the general public.
See how we deal with the information collected:

What are the data types? Personal data:
”Information related to the identified or viral person”, for example: first name, last name, date of birth, personal documents, home or business address, telephone, email and IP address.

Sensitive Personal data:
These are the data that refer to racial or ethnic origin, religious conviction, political opinion, union affiliation or organization of a religious, philosophical or political nature. Sensitive personal data as well are those related to health or sex life, genetic or biometric data.

What data does our Company collect? Our company handles data from employees, partners and service providers, being duly compliant with the LGPD.
On the website, the company collects data through the voluntary and consensual completion of forms, e-books and contact to receive the newsletter.

Is there automatic data collection? Biotimize - Biotechnology as a Service does not automatically collect data in each access to the website.

How do they use my data? The personal data provided by users who fill in the forms are used solely to provide feedback at the user's request (individual or legal entity interested in our company's products and services).
Once the service is completed, such data is deleted.

Have you got any questions? Talk to the Data Protection Manager (DPO) by email: dpo@biotimize.com.br
You will be able to clarify doubts related to the processing of personal data.